PET/CT imaging detect EGFR protein mutations of lung cancer with specific molecular probe 11C-AZD9291

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044457

Enrollment

Unknown

Registered

2021-03-18

Start date

2021-03-10

Completion date

Unknown

Last updated

2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Gold Standard:Detection of gene mutation and 18F-FDG PET/CT in lung cancer tissue

Index test:11C-AZD9291 PET/CT

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Ten volunteers with primary lung adenocarcinoma confirmed by tissue biopsy; 2. EGFR mutation status was confirmed by ARMS fluorescence PCR, including 4 cases of 19del mutant, 4 cases of 21L858R mutant, and 2 cases of wild type; 3. No operation, chemotherapy, radiotherapy or targeted tumor related therapy.

Exclusion criteria

Exclusion criteria: 1. Patients with cardiac pacemakers, defibrillators, hearing aids, insulin pumps and other metal implants; 2. Patients who cannot tolerate PET/CT examination.

Design outcomes

Primary

Measure	Time frame
SUVmax;	—

Countries

China

Contacts

Public ContactZhang Jinming

Chinese PLA General Hospital

Zhangjm301@163.com+86 13801210291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026